WGI-0301 Plus Lenvatinib for Advanced Liver Cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new combination of two drugs—WGI-0301 and lenvatinib—to treat advanced liver cancer (hepatocellular carcinoma) that cannot be surgically removed. It's designed for patients whose cancer has progressed despite prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older with confirmed advanced liver cancer (HCC) unsuitable for surgery
- Cancer has progressed or you couldn't tolerate prior systemic treatments (Phase 1) or prior immunotherapy (Phase 2)
- Good overall health status: able to walk around and do light activities (ECOG 0–1)
- Adequate organ function: liver function tests, kidney function, and blood counts within acceptable ranges
- No major surgery or locoregional liver therapy within 4 weeks of starting the study
- No uncontrolled high blood pressure, heart failure, or significant heart rhythm problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, WGI-0301, for people with advanced hepatocellular carcinoma (HCC, a type of liver cancer) that has progressed after standard treatments. It aims to see if WGI-0301 can help control the cancer when other options have stopped working or caused side effects.
This trial tests a new drug called WGI-0301 combined with the immunotherapy nivolumab for people with advanced liver cancer (HCC) or certain types of kidney cancer (RCC). The goal is to see if this combination can help when standard treatments have stopped working.
This Phase 2 study tests lenvatinib plus an immunotherapy drug (tislelizumab) in people with advanced liver cancer that cannot be removed by surgery and who have hepatitis B infection. The goal is to see if this combination can shrink tumors and slow the cancer down, and to study helpful blood/biomarker signals.
This trial tests a new drug called BL-B01D1, alone or together with other drugs, in people with advanced liver cancer that has not improved with other treatments. The goal is to see if these combinations can help shrink tumors or slow the cancer's growth.
This trial tests new treatment plans for people with advanced liver cancer that has worsened after initial therapy. The goal is to find more effective, personalized options based on how your cancer responds.
This Phase 2/3 study tests whether combining rulonilimab with lenvatinib can control unresectable advanced liver cancer (HCC) that cannot be removed by surgery or treated locally. You may be considered if you have not had prior whole-body (systemic) cancer treatments and your organs and blood counts are strong enough.
Hear when a new Advanced Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.